Actionable news
All posts from Actionable news
Actionable news in LPTN: Lpath, Inc.,

OXiGENE Announces Interim Phase 2 Data for Lead Clinical Candidate CA4P (fosbretabulin) in Neuroendocrine Tumors

-- Biomarker results in first nine subjects add to CA4P evidence of activity --
-- Full results are expected in the second half of 2016 --

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced the presentation of interim phase 2 data for the company's lead investigational drug, CA4P (also known as fosbretabulin). The data were presented in a poster session on October 16 at the North American Neuroendocrine Tumor Society (NANETS) Annual Symposium in Austin, Texas.

Interim data from the first nine subjects in the study suggested that CA4P monotherapy may improve biomarkers and quality of life (QOL) measures. Additionally, CA4P appears to be relatively well tolerated by subjects. The poster also notes that results are preliminary, due to the small number of subjects analyzed at this point.

"The encouraging interim results seen in this Phase 2 study add to the body of evidence showing that CA4P has a positive effect in the treatment of solid tumors," said William D. Schwieterman, MD, OXiGENE's President and CEO. "We look forward to full results from this trial anticipated in the second half of 2016, as we simultaneously move to advance CA4P in later-stage trials in our core programs for ovarian cancer and glioblastoma multiforme, which will evaluate CA4P in combination with complementary, approved anti-angiogenic agents."

The poster presentation, entitled "Phase 2 study (OX4218s) of fosbretabulin tromethamine...